Offer - Urjas Oil for just ₹ 1 X
Atorlip F 5 Tablet is a commercial drug that is prescribed in the form of Tablet. The alternative uses of Atorlip F 5 Tablet have also been explained below.
The right dosage of Atorlip F 5 Tablet depends on the age, gender, and medical history of the patient. The condition it has been prescribed for, and the route of administration also determine the right dosage. Refer to the dosage section for a detailed discussion.
While these are the most often observed Atorlip F 5 Tablet side effects, there are can be others also. These have been listed below. Usually, these side effects of Atorlip F 5 Tablet go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Atorlip F 5 Tablet is Moderate for pregnant women and Moderate for women who are breastfeeding. It is important to know if Atorlip F 5 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Atorlip F 5 Tablet related warnings section.
Atorlip F 5 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Allergy, Kidney Disease, Liver Disease are examples of such conditions.
Drug reaction of Atorlip F 5 Tablet with other medicines has been reported. A complete list of these interactions is given below.
In addition to the above precautions for Atorlip F 5 Tablet, it is important to know that it is safe while driving, and is habit-forming.
Atorlip F 5 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Based on research, the following side effects have been observed when Atorlip F 5 Tablet is used -
Severe
Is the use of Atorlip F 5 Tablet safe for pregnant women?
Pregnant women may experience moderate side effects from Atorlip F. It is best to stop taking Atorlip F immediately and inform your doctor if you notice any discomfort.
Is the use of Atorlip F 5 Tablet safe during breastfeeding?
Breastfeeding women may feel side effects of Atorlip F. If you see any side effects, stop taking Atorlip F immediately and talk to your doctor. Take Atorlip F again, only after your doctor's advice.
What is the effect of Atorlip F 5 Tablet on the Kidneys?
Kidney can be affected by Atorlip F. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Atorlip F 5 Tablet on the Liver?
Atorlip F has very mild side effects on the liver.
What is the effect of Atorlip F 5 Tablet on the Heart?
In the absence of any scientific study on the side effects of Atorlip F on the heart, information on safety of Atorlip F for the heart is unavailable.
Atorlip F 5 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Atorlip F 5 Tablet unless your doctor advises you to do so -
Is this Atorlip F 5 Tablet habit forming or addictive?
No, you will not get addicted to Atorlip F 5 Tablet.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Atorlip F 5 Tablet as it does not make you drowsy.
Is it safe?
Yes, but consume Atorlip F 5 Tablet only on doctor's advice.
Is it able to treat mental disorders?
No, the use of Atorlip F 5 Tablet in mental disorders is not effective.
Interaction between Food and Atorlip F 5 Tablet
Taking Atorlip F 5 Tablet with food does not cause any problems.
Interaction between Alcohol and Atorlip F 5 Tablet
Consumption of alcohol and Atorlip F 5 Tablet together may have severe effects on your health.
Atorlip F is a brand name of atorvastatin which belongs to the class of drugs known as statins (dyslipidemic agents). It is a prescription drug that is used for the treatment of mixed dyslipidemia (high levels of lipids in the blood), hypercholesterolemia (high cholesterol levels), and hypertriglyceridemia.
It has been reported to cause weight gain but only in a few cases, this occurs very rarely. However, the exact cause behind this is unknown. if you notice any unusual weight gain after taking this drug. Then you are recommended to discuss it with your doctor.
Atorlip F comes in form of a tablet and ideally, it should be taken by mouth once daily as advised by your doctor. It can be taken with food or without food at any time of the day. Precautions must be taken in patients with liver disease, diabetes, and hypothyroidism.
Yes, Atorlip F can be taken with ibuprofen. No harmful drug interaction has been reported between them. However, if you feel any discomfort after taking ibuprofen do not hesitate to inform your doctor.
No, use of Atorlip F does not cause memory loss in the patients who are taking it. It has not been reported to cause memory loss.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lipitor® (Atorvastatin Calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 637-638
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Triglide (fenofibrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 639-640
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 551-552